Costs and benefits of routine varicella vaccination in German children

J Infect Dis. 1996 Nov;174 Suppl 3:S335-41. doi: 10.1093/infdis/174.supplement_3.s335.

Abstract

This study assessed the costs and benefits of introducing routine varicella vaccination to healthy children in Germany. Three vaccination strategies were compared with that of no prevention: vaccination of all 15-month-old children: vaccination of susceptible 12-year-olds (adolescent); and a combination of strategies (children including catch-up). From a purely economic viewpoint, the adeolescent strategy was optimal: It was the only one that resulted in net direct cost savings. However, since this strategy may be less acceptable from a medical or organizational point of view and because total net savings were the highest, a second option was to begin immunization starting with the 15-month-old children and to use the catch-up strategy for 11 years (total benefit-to-cost ratio (BCR), 4.72:1; cost-effectiveness ratio (CER), DM 6915 per life-year saved) and from year 12 on to use the first strategy (BCR, 4.60:1; CER, DM 19,735 per life-year saved).

MeSH terms

  • Adolescent
  • Adult
  • Chickenpox / prevention & control*
  • Chickenpox Vaccine / immunology*
  • Child
  • Child, Preschool
  • Cost-Benefit Analysis
  • Germany
  • Humans
  • Infant
  • Vaccination / economics*

Substances

  • Chickenpox Vaccine